Lenvatinib (Lenvima) pour le carcinome hépatocellulaire

Détails

Fichiers
Generic Name:
Lenvatinib
État du projet:
Terminé
Domaine thérapeutique:
Hepatocellular Carcinoma (HCC)
Fabricant:
Eisai
Brand Name:
Lenvima
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0175-000
Statut de l’AC au moment du dépôt:
Post AC
Strength:
4 mg et 12 mg
Tumour Type:
Gastrointestinal
Indications:
Carcinome hépatocellulaire
Funding Request:
Dans le traitement de première intention des patients atteints de carcinome hépatocellulaire (CHC) non résécable.
Sponsor:
Eisai
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.